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Identifying targets for personalized targeted therapy is the pathologist’s domain and
a treasure. For decades, pathologists have had to learn, understand, adopt and im-
plement many new laboratory techniques as they arrived on the scene. Pathologists
successfully integrate the results of those tests into final pathology reports that were,
and still are, the basis of clinical therapeutic decisions. The molecular methods are
different but no more difficult to comprehend in the era of “kit procedures”. In re-
cent years, the development of targeted therapies has influenced routine practices
in pathology laboratories because the use of molecular techniques is required to in-
clude clinically useful predictive information in the pathology report. Pathologists
have the knowledge and expertise to identify particular gene mutations using the
appropriate molecular tests currently available.
This review focuses on the most important recent developments in KRAS mutation
testing in metastatic colorectal cancer (CRC), and shows that a pathologist is involved
in 10 stages of this procedure. Recent studies have shown that highly sensitive, sim-
ple, reliable and rapid assays may significantly improve the identification of CRC pa-
tients resistant to anti-EGFR therapy. Thus, direct sequencing does not seem to be
an optimal procedure of KRAS testing for clinical purposes. Twelve currently avail-
able high-sensitivity diagnostic assays (with the CE-IVD mark) for KRASmutation
testing are briefly described and compared. The suggested pathology report content
for somatic mutation tests is described. In conclusion, evidence is presented that send-
ing away paraffin blocks with tumor tissue for KRAS mutation testing may not be
in the best interest of patients. Instead, an evidence-based approach indicates that
KRAS mutation testing should be performed in pathology departments, only with
the use of CE-IVD/FDA-approved KRAS tests, and with the obligatory, periodic par-
ticipation in the KRAS EQA scheme organized by the European Society of Pathol-
ogy as an independent international body.
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Introduction
For decades, pathologists have had to successfully
learn, understand, adopt and implement many labo-
ratory techniques as they arrived on the scene (e.g., his-
tological, cytological, histochemical, ultrastructural and
immunohistochemical techniques). Pathologists were
able to integrate the results of those tests into final
pathology reports that were, and are, the basis of clin-
ical therapeutic decisions. This does not mean that
pathologists had to perform those laboratory procedures
themselves; rather, they had to understand them and
know how and when to apply them. But, who per-
formed the tests? Biologists employed in pathology lab-
oratories performed the tests. We do not see the ba-
sic difference with the emergence of new molecular
methods. Again, with the advent of molecular meth-
ods pathologists have to understand them and know
how and when to apply them. In many pathology lab-
oratories this understanding has already occurred. In
fact, a continuing education is the first commandment
for a physician in general and the pathologist in par-
ticular. Such education may be painful for some, but
it is necessary. Of course, the integration of new
methodology has always been a team endeavor;
specifically, biologists performed the procedures and
pathologists integrated the results to formulate diag-
noses. In our view, molecular methods are different but
they are not more difficult to comprehend than pre-
vious methods. Molecular methods can be understood,
adopted and implemented by an average pathologist
who can easily learn how to integrate the results into
a pathology report, provided that appropriate training
programs in genomic medicine are organized during
the pathology residency. Molecular biology is not a her-
metic, mysterious knowledge that one cannot master.
In fact, clinically useful molecular biology techniques
are not especially difficult to learn because nowadays
many molecular procedures have been standardized and
greatly simplified. To obtain proper results, just one
major requirement has to be fulfilled, namely faithful
adherence to the detailed manufacturer’s instruc-
tions. It is obvious that pathologists have to cooper-
ate with the molecular biologists employed in their
departments. However, in our view, it is equally im-
portant that pathologists learn the basics of molecu-
lar biology necessary to implement molecular biology
procedures in their laboratories. Therefore, continuous
efforts should be made in this respect during the pathol-
ogy residency period, as well as afterward, in the process
of continuing education.
Pathological diagnosis
In recent years, the development of targeted thera-
pies has influenced the routine practices used in surgi-
cal pathology laboratories. Previously, cancer therapy was
based on the histological type and grade of a tumor
as well as the clinical stage of the disease. With the ad-
vent of targeted therapy, specific predictive information
is sought. The results of an assessment of several pre-
dictive markers (mutations, amplifications, and proteins)
have to be incorporated into the traditional patholog-
ical diagnosis because not all patients derive clinical ben-
efit from targeted therapy. A classic example of targeted
therapies is anti-estrogen therapy, which is successful only
in patients with breast cancer cells expressing estro-
gen/progesterone receptors. Thus, a pathologist must pro-
vide a specific diagnosis and is expected to assess pre-
dictive markers so that patients most likely to respond
to targeted therapies may be identified. Furthermore,
when several protein/molecular targets are identified in
a particular tumor, the development of personalized ther-
apy (in the strict sense of the word) is possible because
several therapeutic options may be revealed that are avail-
able only for a given patient [1].
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Take-home messages:
• KRAS mutation status has emerged as an important predictive marker for anti-EGFR therapy in
patients with mCRC
• A pathologist is involved in KRAS testing in 10 stages of the procedure
• Microdissection should be performed in every case to obtain tissue enriched with tumor cells for
KRAS mutation testing
• The sensitivity of direct sequencing for analysis of KRAS mutations in FFPE tumor samples seems
to be too low to enable its use as a routine clinical test
• The final choice of the CE-IVD-marked KRAS mutation test is largely dependent on
the laboratory equipment, experience and cost of the test
• KRAS mutation testing should be performed in pathology departments, only with CE-IVD/FDA-
approved KRAS tests, and with obligatory, periodic participation in the KRAS EQA scheme
organized by the European Society of Pathology as an independent international body
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Currently, predictive immunohistochemical and mo-
lecular diagnostic tests identify suitable patients for tar-
geted therapy. Therefore, to include predictive infor-
mation in the pathology report, immunohistochemistry
and molecular techniques are required. This simply
means that to provide oncologists with meaningful pre-
dictive information (incorporated into the pathologi-
cal diagnosis), contemporary pathology departments
should be equipped with appropriate laboratories
where molecular techniques necessary to reveal targets
for implementation of targeted therapy can be per-
formed, similar to the setup of contemporary im-
munohistochemical laboratories. Molecular tests can
also be performed outside the pathology department
in certified molecular laboratories. However, in such
situations:
1) there are unnecessary delays associated with the need
to send sections or paraffin blocks, which is not in
the best interest of patients;
2) molecular biologists who perform a test in a mole-
cular laboratory may be unfamiliar with the latest
clinical data related to the molecular alterations test-
ed and the intricacies of pathological, clinical and
therapeutic significance of particular tests;
3) responsibility for the final diagnosis is blurred;
4) the pathologist has a curious role of a distributor
of paraffin blocks/sections and a messenger of pre-
dictive information between a molecular biologist
and a physician. At best, this role is that of a coor-
dinator rather than of a generator of the vital final
pathological diagnosis with predictive informa-
tion.
It may be helpful here to define the meaning
of the term “pathological diagnosis” of tumors.
A pathological diagnosis (report) is obtained on
the basis of microscopic analysis of tissue and/or
cells TOGETHERWITH additional tests (e.g., his-
tochemical, immunohistochemical and, molecu-
lar tests) and clinical data, to provide information
concerning histological type of a tumor AND pre-
dictive/prognostic data.
KRAS mutations
There are three RAS genes in the human genome;
KRAS,HRAS andNRAS. Approximately 15-20% of all
human neoplasms contain RASmutations. Mutations
in the KRAS gene are detected in 35-45% of CRCs
[2-8], whereas NRAS and HRAS mutations are only
found in 1-3% of CRCs. KRASmutations are frequent
in pancreatic, colorectal, biliary tract, and lung cancers.
The most common KRASmutations in CRCs are found
in codons 12 (~77% of mutations) and 13 (~20%
of mutations) in exon 2 of the gene. Much less frequent
are mutations in codons 61 (1%) and 146 (0.5%) (data
from the COSMIC database v60) [9]. Somatic missense
mutations in codon 12 of the KRAS gene, resulting in
a single amino acid substitution (p.Gly12Val), are
the most common abnormalities in CRCs.
RAS/EGFR signaling pathway
The KRAS gene encodes a small GTPase protein
(G protein) that functions downstream of EGFR-induced
cell signaling, and participates in the activation of im-
portant oncogenic signaling pathways. The RAS pro-
tein is a key element of the RAS-MAPK intracellular
signaling pathway, which is triggered by EGFR tyro-
sine phosphorylation of the intracellular domain
of the receptor. This triggering results in the activa-
tion of several other signaling pathways that control
gene transcription, cell proliferation, apoptosis, an-
giogenesis, invasion and migration [10]. Therefore,
the EGFR signaling system is regarded as crucial to
the regulation of the growth, proliferation and ma-
lignant transformation of epithelial cells.
RAS proteins, which act as signal transducers, nor-
mally cycle between active (RAS-GTP) and inactive
(RAS-GDP) conformations. RAS proteins are activat-
ed by guanine nucleotide exchange factors (GEFs) and
inactivated when RAS-GTP is hydrolyzed to RAS-GDP
by GTPase-activating proteins (GAPs). In normal cells,
the activities of GEFs and GAPs are tightly controlled
and the RAS-GTP level is kept in check. Mutations in
RAS result in markedly reduced the intrinsic GTPase
activity of RAS proteins and make these proteins re-
sistant to the GAPs. Thus, mutated RAS proteins per-
manently remain in the RAS-GTP active form and con-
tinuously activate signaling pathways without
stimulation of the HER family of cell surface receptors
[11-14]. Such an activating mutation may induce an
oncogenic transformation or confer resistance (insen-
sitivity) to anti-EGFR antibody therapies due to per-
manent, EGFR-independent activation of both
the PI3K/AKT and MAPK pathways.
Mutations in KRAS as predictive markers
for anti-EGFR treatment in patients with
metastatic colorectal cancer
Given the EGFR independent activation of KRAS
it is not surprising that, anti-EGFR antibodies will not
be effective in patients with metastatic CRC (mCRC)
with a KRASmutation. Indeed, an association of KRAS
mutations in CRC with resistance to anti-EGFR mono-
clonal therapy was reported [15, 16]. These results
were subsequently confirmed in independent retro-
spective studies [17, 18]. Finally, supportive evidence
of predictive significance of KRASmutations for anti-
EGFR treatment of mCRC was obtained from phase
II and III clinical trials of the anti-EGFR monoclonal
antibodies cetuximab and panitumumab used either
as monotherapy or in combination with chemothera-
py in patients with mCRC (references in [19]). For ex-
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ample, single-agent, randomized, controlled trials
with cetuximab [20] and panitumumab [21] re-
vealed no benefit from these anti-EGFR therapies in
KRAS-mutant mCRCs patients. In a study of second-
or third-line treatment of mCRC patients with ce-
tuximab, the statistically significant differences between
the antibody arm and control arm were 12.8% vs. 0%
for response rate, 3.7 months vs. 1.9 months for pro-
gression-free survival and 9.5 months vs. 4.8 months
for median overall survival [20]. In April 2009, based
on an analysis of five randomized controlled trials of ce-
tuximab or panitumumab and five single-arm retro-
spective studies, the following provisional clinical
opinion of the American Society of Clinical Oncology
was issued: “…all patients with mCRC who are can-
didates for anti-EGFR antibody therapy should have
their tumor tested for KRASmutations in a CLIA-ac-
credited laboratory. If a KRAS mutation in codon 12
or 13 is detected, patients with mCRC should not re-
ceive anti-EGFR antibody therapy as part of their treat-
ment” [19]. Both the European Medicines Agency
(EMEA) and the U.S. Food and Drug Administration
(FDA) approved the use of cetuximab and panitu-
mumab for treatment in patients with wild-type
KRASmCRC. However, there are differences in those
approvals. The EMEA approved both drugs for
the treatment of patients with wild-type KRASmCRC
in 2007 without mentioning methodology or the ex-
act mutations to be tested. In contrast, the FDA spec-
ified the testing for mutations in codon 12 or 13 of
KRAS in their recommendations issued in 2009 and,
in addition, required that two conditions be met: val-
idation of a single assay for mutation detection and re-
assessment of all randomized clinical trials with this as-
say. In July 2012, the FDA approved the TheraScreen
kit to be sold as a companion diagnostic test for ce-
tuximab. Furthermore, the FDA has additionally ap-
proved the use of cetuximab in combination with
FOLFIRI (5-fluorouracil, irinotecan, leucovorin) as
a first-line treatment in patients with mCRC and EGFR-
expressing and wild-type KRAS tumors. Thus, KRAS
mutation status has emerged as an important pre-
dictive marker for anti-EGFR antibody therapy in
patients with mCRC. The clinical trial data briefly
summarized above strongly support the recommen-
dation that patients whose CRCs do not have KRAS
mutations should be treated with anti-EGFR mono-
clonal antibodies, and that those with KRASmutations
should not be treated with this therapy. The results de-
scribed above pertain to KRAS mutations in codons
12 and 13 of exon 2. Recent reports suggest that al-
though rare KRAS exon 3 mutations may also be as-
sociated with a lack of response to anti-EGFR mono-
clonal antibodies [22]. However, the examination
of KRASmutations in exon 3 does not significantly im-
prove the identification of non-responding mCRC pa-
tients.
Thus, the presence of KRASmutations has become
widely accepted as a negative predictive marker for anti-
EGFR monoclonal antibody therapy in mCRC patients.
However, in the future, the presence of these mutations
may also become a positive predictive marker for ther-
apies based on the inhibition of KRAS activation or
the inhibition of alternative downstream kinases in
KRAS-mutant mCRC patients. There are several on-
going preclinical studies and clinical trials utilizing dif-
ferent therapeutic approaches in this respect, e.g.,
BRAF inhibitors in BRAF-mutant mCRCs, MEK in-
hibitors, farnesyltransferase inhibitors, and SFK inhib-
itors (e.g., dasatinib), which may sensitize KRAS-mu-
tant mCRCs to cetuximab (dual kinase inhibition) [23].
These new therapeutic approaches only underscore
the clinical importance of KRAS testing for the targeted
therapy of patients with mCRCs.
Key role of the pathologist in the assessment
of therapeutic targets in general and KRAS
mutation testing in particular
A pathologist is involved in KRAS testing in 10 sta-
ges of the procedure.
1) A pathologist decides on the method of tumor tis-
sue collection for KRAS testing prior to DNA ex-
traction. There is no consensus recommendation
for this step, although general recommendations
have been made (by CAP [24] and NCCN [25])
regarding the process of tissue collection. From
a practical point of view, buffered formalin-fixed,
paraffin-embedded (FFPE) tumor tissue is most
commonly used for KRAS testing. Testing may also
be performed on fresh tissue stored in a preserva-
tive solution (e.g., RNAlater [Ambion]), rapidly
frozen and stored tissue [19] or formalin-free fixed
tissue [26, 27].
2) A pathologist identifies sources of tumor material
for the assessment of KRAS mutation status. Ac-
cording to the National Comprehensive Cancer Net-
work’s (NCCN) clinical practice guidelines [25], ei-
ther primary or metastatic tumors can be used for
KRAS testing. Based on results showing a high lev-
el of concordance between KRAS mutation status
in primary vs. metastatic CRCs [28, 29] and ob-
servations indicating that KRASmutations may oc-
cur early in the progression of CRC, there is a con-
sensus opinion that in metastatic disease KRAS
testing of the primary CRC provides conclusive re-
sults. Because archival paraffin blocks from the pri-
mary tumor are available in the majority of cases
of metastatic disease, there is no need for biopsy
of a metastatic tumor. When a patient presents with
metastasis at the initial diagnosis, a metastatic tu-
mor biopsy may be used for the KRAS test. When
post-radiochemotherapy low tumor cellularity is
found in a specimen, pre-treatment biopsies repre-
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sent the most cost-effective option for reliable
KRAS genotyping [30].
3) A pathologist is responsible for the selection and eval-
uation of the tumor tissue block.A pathologist makes
the judgment as to whether there is sufficient quan-
tity and quality of tumor material to be used in DNA
extraction for KRAS testing (see below). The amount
of tumor tissue in the specimen and the general qual-
ity of the collected tissue and extracted DNA have
important implications for the accuracy and sensi-
tivity of the KRAS testing method used [31].
4) A pathologist is responsible for tumor cell enrich-
ment in a target tissue sample. To increase the sen-
sitivity of mutation testing, several methods may be
employed to enrich the tested sample in tumor cells,
e.g., macrodissection, manual microdissection or laser
microdissection (see below). All of these tech-
niques require the user to be familiar with microscopy
and histopathology [32].
5) A pathologist chooses the method to be used for
KRAS testing in the laboratory. To make a well-
informed decision regarding the testing method to
be used, the pathologist should consult with a mol-
ecular biologist and take into consideration the DNA
amount and quality required, time to obtain results,
accuracy, sensitivity and the cost of the preferred
method (see below and Table I). Each method has
its advantages and disadvantages. However, although
traditional Sanger sequencing detects all clinically-
important KRASmutations, its sensitivity is too low
to be used as a routine clinical test (mutant alleles
must be present in at least 30-40% of cells for re-
producible detection) [2, 33-35]. To the best of our
knowledge, there are currently 12 highly sensitive,
simple, rapid CE-IVD-marked diagnostic assays for
KRASmutations (see below and Table I). The min-
imal requirements that a KRAS test should satisfy
include: a specificity of 100% and a mutation de-
tection sensitivity of between 95 and 99% [36]. It
is clear that increasing the sensitivity of the meth-
ods used to detect KRAS mutations can greatly
improve predictions of resistance to anti-EGFR treat-
ment [37-41]. Therefore, high sensitivity of the
method is a key issue.Due to the intratumoral het-
erogeneity of KRAS mutations [42-45], clones
bearing KRASmutations may be undetected by di-
rect sequencing [37, 41], and tumor cells from these
clones may exhibit an increased propensity for dis-
tant metastases [37].
6) A pathologist, together with a molecular biologist,
actively participates in the laboratory procedure for
KRAS testing. Pathologists should be aware
of the types of procedures used and their pros and
cons, and specifically, they should be familiar with
the details of the procedures used in his or her de-
partment. Test data should be analyzed and discussed
Table I. Comparison of KRAS genotypes detected by CE-IVD-marked commercial kits, frequency of their appearance
in CRCs and cost per sample. Green boxes highlight mutations that are detected by a particular kit
CE-IVD APPROX. A.A. MUTATIONS AND THEIR FREQUENCY IN CRC (%)b
KRAS KIT COST PER G12A, G12C G13C G13S G13A Q61H Q61L Q61K Other
SAMPLE G12D, G12R (0.5) G13R G13V (CAT) Q61R Q61E
(USD)a G12S, G12V (0.3) G13I Q61H (0.3) Q61P
G13D G12F (CAC) (0.1)
(96.2) (0.3) (0.5)
TheraScreen PCR 210
AmoyDx 117
PNAClamp 70
RealQuality 50
EntroGen 77
LightMix 57 d
StripAssay 77 e
Hybcell plexAc 124
Devyserc 40
Surveyorc 26 f
Cobasc 81
TheraScreen Pyroc 124 g
aAccording to price quotes (net) available in Poland (August 2012). Cost calculated per sample when the maximum number of cases is tested in a batch (the optimum
circumstances). This is only the kit cost per sample and does not include the costs of shipping, DNA isolation and quantification, repeat tests or labor cost; bThe mutation
frequency (CRCs only) was obtained from the COSMIC database v60; cRequires equipment other than that used for real-time PCR; dG12T; eG12I and G12L; fother
mutations in exon 2; gother mutations in codons 12, 13, and 61
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jointly by the pathologist and molecular biologist.
The pathologist is also involved in the continuous
review process of new technologies and publications
on KRAS mutation testing.
7) A pathologist writes the results of a KRAS test in
a special report that is understandable to the on-
cologists. TheKRASmutation report, similar to the re-
port of any molecular test of clinical significance, should
contain items listed in Table II [19, 36, 46-54]. If
a mutation is identified, the affected codon and the spe-
cific change should be reported. This is an important
aspect of the report because recommendations for
treatment eligibility are continuously evolving.
8) A pathologist provides the interpretation of results
in terms of their predictive significance. The pathol-
ogist should report the results of KRAS testing, as
well as their therapeutic significance, in the partic-
ular clinical context of a patient. The interpretation
of results should be clear and accurate in view
of the findings described above (in the paragraph
“Mutations in KRAS as predictive markers for
anti-EGFR treatment in patients with metastatic col-
orectal cancer”) and the most recent literature
data. The interpretation of the genomic information
should assist a physician in therapeutic decision-
making, i.e., to help predict which patients are most
likely to benefit from anti-EGFR monoclonal anti-
body treatment. Specifically, it should be noted that
a wild-type result does not rule out the presence
of rare mutations not tested by the assay used. More-
over, it should be added that not all patients with
wild-type KRAS cancers will respond to anti-
EGFR antibody therapies, the predictive informa-
tion of the KRAS test applies only to anti-EGFR
monoclonal antibody therapy and not to other types
of therapies, and KRAS mutation tests in metasta-
tic and corresponding primary cancers are discordant
in less than 5% of cases [55].
9) A pathologist is responsible for the turnaround time
of the report. A recent survey of KRAS testing re-
vealed that test results were available within 15 days
for 82%, 51% and 98% of tested patients in Europe,
Latin America and Asia, respectively [56]. In another
study, the results were obtained with a mean delay
of 33 days [57]. Although it seems that a delay of
10-14 working days is acceptable [47], an effort
should be made to make the report available in
a shorter time (one has to keep in mind that a pa-
tient with metastatic CRC is waiting for this test and
the therapeutic decision).The turnaround time can
be substantially shortened if the whole proce-
dure is performed in the pathology department
that provided the histopathological diagnosis
of CRC. In fact, in our experience, KRASmutation
test can be done and the report issued in three
working days, starting from the date on which
the test was requested.
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Table II. Pathology report content for a somatic muta-
tion test. A checklist
GENERAL INFORMATION
 Report title1
 Name and address of the reporting institution
 Name and address of the requesting institution
and name of the requesting oncologist
 Date of the request form (if material comes from
the same pathology department where mutation test
will be performed) or date of arrival of the sample
with the request form
 Date of the report
 Own reference number of mutation test
 Total number of pages and page numbers (e.g., 1 of 2)
CPT codes2
Cite references for report facts
PATIENT INFORMATION
 Name and age
 ID number or date of birth
Short clinical history
SAMPLE INFORMATION
 Sample number
 Nature of the sample (e.g., FFPE3, fresh frozen,
or biopsy)
 Tumor origin (e.g., primary, metastatic, or recurrent)
 Sample adequacy, e.g., satisfactory for evaluation
or unsatisfactory for evaluation (specify reason)
Percentage of tumor cells4
METHODS USED
 Identification of the best block with the highest
percentage of tumor cells: yes or no
 Method of tumor cell enrichment: macrodissection,
microdissection, or none
 Method of DNA isolation
 Method of genotyping
 Name of the diagnostic kit (CE-IVD/FDA-approved)
 Sensitivity of the method
 List of mutations that were tested5
RESULT
 Genotype5
 Interpretation regarding the treatment6
 Comments7 (if applicable)
RESPONSIBILITY
 Signatures8 and printed names of the molecular
biologist and pathologist involved in performing
the test and interpreting the results
The optional items in each section are shown (without a checkbox) in italics.
1Should include the name of the tested gene(s) clearly distinguished from the rest
of the report; 2Current Procedural Terminology (CPT) codes document the analytical
and interpretative procedures that are performed in the laboratory; 3Formalin buffered
or not; 4If the test was performed without microdissection and/or a low sensitivity
method was used; 5Nomenclature according to HGVS guidelines; 6Example: presence
of KRAS mutation indicates likely resistance to anti-EGFR therapy; 7Examples:
recommendations for further testing; condition of a specimen that may limit the adequacy
of testing; reason why a specimen was rejected or not processed to completion; if the report
is an amended or addendum report, a description of the changes or updates; 8Reports
may be signed electronically
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10) A pathologist is responsible for the implementa-
tion of an external quality assurance (EQA) pro-
gram in the molecular diagnostic laboratory
of the pathology department in which he or she
works. We share the well-founded opinion that ev-
idence-based approaches require EQA programs for
KRAS testing (see below).
In summary, the pathologists looking down
the microscope remain the final decision makers
[58]. They may seek advice from molecular biol-
ogists and oncologists but the final diagnostic de-
cision and the responsibility is theirs. Certainly,
“…genomic analysis in the absence of pathologic as-
sessment risks the generation of meaningless results”
[59]. Currently a pathology report that is meaningful
to the oncologist as well as to the patient includes a di-
agnostic algorithm integrating conventional histopathol-
ogy with immunohistochemistry [60] and disease-spe-
cific molecular tests.
KRAS testing as a routine test necessary
to provide predictive information
in pathology reports of colorectal cancer
Because the assessment of KRASmutations has be-
come an important aspect of management of mCRC
patients, there is an urgent need to establish and agree
on the best laboratory procedures to ensure accurate
assessment of KRAS status. A routine predictive test
should be relatively simple to perform, fast, reliable (in
terms of sensitivity and specificity) and not too ex-
pensive. Contemporary somatic mutation testing
has taken the form of a “kit procedure”. It is sim-
ple, fast and reliable, provided that a test that is ap-
proved by the appropriate national or international
agencies is used, the producer’s protocol is rigorously
followed, and an EQA program is implemented by
the laboratory. Below, we briefly describe the most im-
portant aspects of KRASmutation testing procedures
in which FFPE CRC tissue is used. Currently, FFPE tis-
sue is widely used in KRAS testing, but fresh-frozen
tissue or cytological material can also be clinically use-
ful.
Selection and evaluation of the tumor tissue
block
Although somatic mutation analysis does not require
a pure cell population, tumor cellularity is a critical is-
sue. A pathologist responsible for selecting a paraffin
block for molecular tests should choose one that has
the greatest percentage of invasive cancer cells and avoid
blocks with many lymphocytes, necrosis or extracel-
lular mucin. These factors can diminish the sensitivi-
ty of the technique, particularly if direct sequencing is
used [61]. It has to be kept in mind that genotyping
is performed on genomic DNA of both tumor cells and
benign stromal cells of tumor microenvironment.
Thus, sections for the test should be taken from blocks
containing tumor tissue enriched with intact cancer cell
nuclei. International guidelines suggest that the spec-
imen should contain a cancer cell percentage of at least
70% if a low-sensitivity technique, such as direct se-
quencing of the PCR product, is used [46]. In any case,
the specimen should contain at least 100 cancer cells
[62].
Evaluation of the tumor’s contents is a subjective pro-
cedure that depends on both the region selected and
the assessment of the ratio between the cancer cells and
normal nucleated cells. High inter-observer variabil-
ity has been reported in the estimation of the percentage
of cancer cells in hematoxylin and eosin (HE) stained
sections. An EQA study involving 13 experienced lab-
oratories revealed large differences in the estimates
of this percentage in the same samples, varying from
9 to 90% or from 32 to 95%. There was no consistent
pattern in the estimates between different laboratories
[31, 47, 63]. These differences may be partially ex-
plained by incorrect measurement of the percentage
of the sample area that is tumor, instead of the per-
centage of nuclei that are in the tumor [64], which is
more difficult to measure with the naked eye. Further-
more, large differences in the diameter of tumor cell
nuclei and the nuclei of the neighboring benign stro-
mal cells make the estimation of tumor DNA content
difficult and imprecise, and usually the contribution
of normal cell nuclei to total DNA content is under-
estimated. Thus, the histological assessment of tumor
cell percentage can serve only as a very rough estimate
of tumor DNA content in the corresponding extract
[65, 66]. For the above reasons, tumor cell enrichment
is necessary for genotyping with FFPE tissue.
Macrodissection and microdissection
The percentage of cancer cells in the specimen and
the general quality of the collected tissue and extracted
DNA have important implications for the accuracy and
sensitivity of the KRAS testing method used [31].
The target tissue will always contain some normal cells
within the tumor microenvironment (e.g., lymphocytes,
macrophages, endothelial cells, and fibroblasts). To in-
crease the sensitivity of mutation testing, several
methods may be employed to achieve cancer cell en-
richment in tested material, e.g., macrodissection, laser
microdissection, and manual microdissection.
Macrodissection. In this method, HE-stained
slides are examined and the enriched tumor cell area
is marked by a pathologist on a HE-stained slide that
will be used as a template for macroscopic dissection
(without the microscope) of the consecutive slide(s).
The area corresponding to the area marked on
the template HE slide is scratched off using a sterile,
single-use scalpel.
KRAS MUTATION TESTING IN COLORECTAL CANCER
151
Laser microdissection. This is the most accurate
technique to separate tumor cells from benign stromal
cells. However, it is time-consuming and requires very
expensive equipment. Therefore, it cannot be recom-
mended for routine use in every case. In our experience
and that of others [67], in some cases where tumor cel-
lularity is low or tumor cells are dispersed (e.g., small
biopsy, cytology specimens, or post-radiochemother-
apy samples), isolation by laser microdissection results
in a purer population of tumor cells for mutation de-
tection and is a more sensitive method compared with
other methods.
Manual microdissection. This simple technique is
more accurate than macrodissection and less meticu-
lous than laser microdissection. It can be performed on
unstained tissue, but the best results are obtained us-
ing stained tissue sections, enabling the procurement
of tissue compartments (even as small as 1 mm2) much
faster than laser microdissection and more accurately
than macrodissection [68]. For manual microdissection,
the tumor area is dissected by a pathologist under a light
microscope (standard or inverted). The compartments
without cancer cells are removed with a scalpel or in-
jection needle, and the remaining tissue fragments (con-
taining nearly all cancer cells) are removed (scratched)
into a test tube for further treatment (one can also place
the cancer cells into a test tube first). Almost any his-
tological staining (e.g., cresyl violet, methyl green, meth-
ylene blue, toluidine blue, and nuclear fast red) can be
used to visualize nuclei in sections selected for DNA or
RNA molecular analysis, because the staining does not
interfere with DNA and RNA testing [69]. Although
some older studies reported that HE staining inhibit-
ed DNA amplification by PCR [70, 71], recently pub-
lished data [69, 72, 73] provide no evidence for
the interference of HE staining with DNA testing. These
results suggest that DNA from HE-stained sections can
be effectively used for routine DNA testing, which is
especially important when only HE-stained slides, and
not tissue blocks, are available. Then, after the HE slides
are scanned, somatic mutations can be directly tested
from routinely stained HE sections.
Manual microdissection is a powerful tool to enrich
the analyzed sample with tumor cells. Recent research
on the reported clinical benefit associated with high-
ly sensitiveKRAS detection methods suggests that man-
ual microdissection will become an indispensable rou-
tine method to obtain tissue enriched with tumor cells
for the analysis of somatic mutations. In this approach,
subjective counting of the relative frequency of neo-
plastic cells in a tissue sample may be avoided because
manual microdissection, together with highly sensitive
diagnostic KRAS tests, assures a high level of sensitivity
and repeatability. Thus, in our opinion, manual mi-
crodissection should be performed in every case
to obtain tumor tissue of the appropriate quality
and quantity for KRAS mutation testing.
DNA isolation
DNA quality is one of the most important factors
when performing DNA mutation assays in FFPE tis-
sue; therefore, the DNA extraction methodology is crit-
ical. The formation of DNA-protein cross-links due to
the formaldehyde solution leads to nucleic acid frag-
mentation but at the same time, nucleases are deac-
tivated (- a stabilizing effect). Thus, while molecular
templates from FFPE tissue are of inferior quality com-
pared with those from fresh-frozen tissue, they may still
be useful for nucleic acid assessment with recently de-
veloped methods (even for microarray profiling and wide
genome scans), and results from FFPE tissue are large-
ly comparable with data obtained from fresh-frozen ma-
terial [65, 74-76]. The main advantage of using FFPE
tissue for molecular analyses in cancer research is
the possibility of achieving an accurate correlation
of the results with tissue histology and with long-term
follow-up data. This ability is especially important in
rare subtypes or subpopulations of cancers. Another ad-
vantage is the availability of FFPE tumor tissue for
the assessment of predictive markers when new targeted
therapies are developed in the future.
There are plenty of “in-house” methods and com-
mercially available kits specially designed for DNA iso-
lation from FFPE tissue. The aim of these methods is
to increase the DNA yield from FFPE tissue, and they
involve steps to reverse modification of nucleic acids
by formaldehyde. The highest amount of DNA was ob-
tained using the phenol-chloroform extraction method
[73, 77-79] or the WaxFree DNA kit (TrimGen,
Sparks, MD, USA) [78, 79]. However, the quality
of the real-time PCR reactions is quite often compro-
mised when using isolates with increased quantities
of DNA [78]. Furthermore, spectrophotometric analy-
sis revealed that DNA extracted with the use
of the WaxFree DNA kit was of poorer quality com-
pared with that obtained with the use of phenol-chlo-
roform, silica-based columns (QIAamp DNA FFPE Tis-
sue kit, Qiagen, Hilden, Germany) or rapid glass-fiber
filters (RecoverAll kit, Ambion, Austin, TX, USA) [79].
Munoz-Cadavid et al. [80] recently evaluated the ex-
traction of high-quality DNA from FFPE tissue in
5 commercial kits and found that the best results were
achieved with the TaKaRa Dexpat Kit (Takara Bio, Shi-
ga, Japan) and the QIAamp DNA FFPE Tissue Kit.
The Qiagen extraction kit was the most popular DNA
extraction method for FFPE tissue in the European So-
ciety of Pathology (ESP) KRAS EQA program [47].
DNA obtained from FFPE samples that allow
the amplification of 300 bp is considered to be good-
quality DNA and can be used for many molecular tests
[81]. For tests that require a standardized input
of DNA (e.g., multiplex PCR, MLPA, and array-CGH),
isolation methods based on silica columns should be rec-
ommended. For general molecular tests (e.g., mutations
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and translocations), a simple, rapid and less expensive
protocol for DNA isolation (without precipitation or
purification) may be sufficient [81-83].
Assessment of DNA quality and quantity
Widely used methods based on measurements
of UV absorbance do not always allow for an assess-
ment of the availability of a material for molecular tests.
Common biological contaminants of extracted DNA
such as proteins, RNA, and chaotropic salts from ex-
traction procedures can increase the spectrophotometric
estimation of DNA concentration [84]. Imprecise meas-
urements may be particularly harmful when further mo-
lecular analysis requires the precise assessment of DNA
content in the material studied.
Therefore, for the assessment of the quality
of DNA extracted from FFPE tissue that is to be used
for molecular tests, methods based on DNA-binding
dyes fluorescence, real-time PCR DNA amplification
or PCR with agarose gel electrophoresis are more use-
ful than spectrophotometric analysis. The main ad-
vantage of real-time PCR-based analysis is the abil-
ity to assess how much of the available nucleic acid
sample is amplifiable. Drawbacks of this method in-
clude the expensive proprietary reagents, primers, and
probes needed to perform the assays, the lengthy as-
say time, and the fact that sample volume has to be
expanded [85].
Fluorometric measurement of DNA concentration
has gained popularity because it is simple and much
more sensitive than absorbance measurements [86]. Flu-
orometric analysis is not as accurate as real-time PCR,
but it is much faster, less expensive and simpler; there-
fore, it appears to be the optimal approach to the quan-
tification of DNA for molecular analysis of FFPE tis-
sue.
Commercially available real-time quantitative
PCR kits for clinical KRAS mutation analysis
of FFPE tissue as a better alternative to direct
sequencing
Several molecular techniques characterized by dif-
ferent sensitivities, specificities and complexities are cur-
rently used in research and clinical studies for the de-
tection of KRAS mutations in FFPE tumor samples.
Some techniques require expensive equipment and
reagents, whereas other methods can be easily adapt-
ed for use in molecular laboratories of departments
of pathology without the need for additional machines
[87, 88]. Until recently, the most widely available meth-
ods for KRAS testing were Sanger sequencing and a va-
riety of “in-house” developed laboratory tests. How-
ever, these methods are subject to great inter- and
intra-laboratory variability and are not always prone
to adequate Quality Control schemes that ensure re-
producibility of results [89].
In general, the advantage of sequencing-based
methods is the ability to detect all clinically important
KRASmutations. However, direct sequencing has sev-
eral limitations: (1) it is time consuming and labor in-
tensive; (2) interpretation is subjective if the signal/noise
ratio is low; and (3) it has low sensitivity compared with
other methods. A mutant allele percentage of more than
5 to 10% is required for detection of mutant tumor cells
in pyrosequencing, and a percentage of 30 to 40% is
needed for Sanger sequencing [33, 34, 61, 90].
The detection of mutations by direct sequencing
of cytological specimens, small tumor biopsies or tu-
mors containing a high percentage of non-neoplastic
cells, may lead to false-negative results [88]. Bando et
al. [2] suggested, on the basis of their experience and
literature data, that direct sequencing should be dis-
carded as the method of choice in clinical KRAS test-
ing because with this method, approximately 25%
of patients selected for anti-EGFR therapy will not re-
ceive any benefit. Thus, the sensitivity of direct se-
quencing seems to be too low to be used as a rou-
tine clinical test for the analysis ofKRASmutations
in FFPE tumor samples.
The development of commercial real-time quanti-
tative PCR assays offers a useful alternative because they
are simple, labor-saving (in our experience the proce-
dure takes about 3 h) and more sensitive than direct
sequencing [2, 37-41, 61, 88, 91-100]. Further-
more, because they avoid post-PCR handling, the risks
of contamination and generation of false-positive re-
sults are greatly reduced [101]. Real-time PCR meth-
ods yield informative results even in cases with very frag-
mented DNA, whereas only samples with relatively
well-preserved DNA can be accurately analyzed with
direct sequencing [65]. The per-sample cost of muta-
tion test with clinically validated methods (CE-IVD-
marked) is significantly higher compared with the per-
sample cost using direct sequencing. However, costs
of labor, assay development and validation of the
method are not included in the assessments of the se-
quencing method. Moreover, basic equipment for real-
time quantitative PCR tests is less expensive (than that
for sequencing), and the molecular tests can be per-
formed in most pathology departments with molecu-
lar diagnostic laboratories with real-time PCR machines.
Clinical significance of high-sensitivity KRAS
testing
In some CRCs, KRASmutations may be present in
only a small subset of tumor cells (clonal heterogene-
ity). The failure to find such mutated clones that may
be associated with treatment resistance, substantially
limits the ability to predict treatment response [41, 91,
102].
Recent studies have shown that highly sensitive, sim-
ple, reliable and rapid assays may significantly improve
the identification of CRC patients resistant to anti-EGFR
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therapy. With such techniques, it is possible to detect
KRASmutations in a subset of tumors that seem to be
wild-type when tested with direct sequencing. Using
high-sensitivity methods, Molinari et al. [37] identi-
fied up to 11% additional KRASmutations compared
with direct sequencing, and Malapelle et al. identified
8% more KRASmutations in patients not responding
to cetuximab. Similarly, it has been reported that KRAS
mutation testing by highly-sensitive methods and qual-
ity-controlled KRAS assays, may more closely corre-
late with the clinical effects of anti-EGFR antibody ther-
apy than direct sequencing [38, 39], and it has also been
reported that such mutation testing is useful for
identifying true responders to cetuximab [40]. It should
be noted that anti-EGFR monoclonal antibodies have
been registered for treatment on the basis of results ob-
tained using highly sensitive techniques of KRASmu-
tation testing in mCRCs [21, 103-106] and lung can-
cers [107]. Thus, high-sensitivity KRAS detection
methods improve the prediction of benefit from tar-
geted therapy, thereby justifying their use for routine
KRAS testing.
Even in microdissected tumor material, mutant se-
quences in DNA isolate can be rare, and more sensi-
tive methods than direct sequencing may be required
for mutation analysis. One can imagine that a perfect
approach would be the combination of manual mi-
crodissection (under the microscope) with high-sensi-
tivity (1% mutants in a 99% wild-type background lim-
it of detection) methods for KRAS mutation testing.
For example, if a microdissected material contains ap-
proximately 90% cancer cells, a subpopulation of ap-
proximately 1-2% of mutant cells can be detected.
The requirement of such a high level of sensitivity in
detecting mutant tumor cells does not seem exceptional
if we consider that, to predict the response to hormonal
therapy in breast cancer, an ER/PR positive tumor cell
level as low as 1% is required to expect a significant
clinical response [108].
Diagnostic assays for KRAS mutation testing,
with the CE-IVD mark
After December 7, 2003, in vitro diagnostic (IVD)
assays offered for sale in EU member countries are re-
quired to conform to IVD Directive requirements
(98/79/EC) and to be CE-IVD-marked [109]. Tests
without the CE-IVD mark are only acceptable for re-
search. In the USA, similar but more restrictive FDA
regulations have been in effect for many years.
The CE-IVD mark guarantees that the product
achieved the performance stated by the manufactur-
er on a variety of test parameters, such as limits of de-
tection, analytical sensitivity and specificity, repro-
ducibility/repeatability, and potential interfering and
cross-reacting substances [110]. Nevertheless, it is sur-
prising that, despite the EU regulations, direct se-
quencing and other “in-house” developed techniques
were the most frequently used methods for clinical
KRAS testing, as shown by the results of ESP-EQA
2011 program, in which the competence of participating
laboratories (mainly from member states of the Euro-
pean Union) in providing clinically useful reports was
assessed [111]. To the best of our knowledge, there are
currently 12 commercially available CE-IVD-marked
KRAS mutation kits available in Europe for diagnos-
tic use that can be divided into three categories: real-
time PCR-based, sequencing-based and DNA hy-
bridization-based tests. The pros and cons of these assays
are briefly described below.
TheraScreen PCR and Pyro. The TheraScreen PCR
(earlier DxS, now a Qiagen company) was the first clin-
ically validated, CE-IVD-certified (2009) and FDA-ap-
proved (and currently the only commercially available
KRAS test that is FDA-approved – for use on the Ro-
tor-Gene Q instrument; 2012) diagnostic kit for
the assessment of tumor-specific mutations in patients
with CRC. It is a frequently used commercial KRAS
test in Europe and the USA. In the ESP KRAS EQA
scheme 2011, this kit was used by 23% of participants
[111]. The kit detects six mutations in codon 12 and one
mutation in codon 13 of the KRAS oncogene (Table I).
The TheraScreen PCR kit (Qiagen, Manchester, UK)
combines two methods, namely: ARMS (Amplification
Refractory Mutation System) and Scorpions in real-time
PCR reactions. In these PCR reactions, matched (mu-
tant-specific) primers are efficiently amplified compared
with mismatched primers (only low-level background
amplification occurs). The real-time PCR assay is used
to assess the quantity of mutant vs. wild-type sequences
in the sample. An example of data acquisition is shown
in Figure 1. The TheraScreen Pyro kit is the first clin-
ically validated, CE-IVD-marked test for pyrose-
quencing-based detection of KRAS mutations in
codons 12, 13 and 61 dedicated for use in the Pyro-
Mark Q24 system.
Recent reports suggest that the TheraScreen PCR
kit has a significantly higher sensitivity compared with
sequencing, even in samples with optimal tumor cell
content [2, 61, 92-94]. Angulo et al. [61] compared
the true sensitivity of direct sequencing with that
of the TheraScreen PCR kit. When the mutant DNA
represented 5% of the total DNA, the TheraScreen PCR
kit detected mutations in 84% of the samples. This sen-
sitivity was much higher than that obtained by direct
sequencing, in which mutations were detected in 19
and 76% of the samples if mutant DNA constituted
5 and 30%, respectively. This test increases the detection
percentage of KRAS mutations by 7-25% compared
with direct sequencing [2, 92-94]. The limit of detection
(LoD) of this assay (derived from cell lines) is 1% mu-
tants in a 99% wild-type background [112]. Small in-
tra- and inter-lot deviations and a good concordance
among the different real-time PCR systems suggest-
ed the reliability of this test for clinical use [113]. Ad-
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Fig. 1. Flow chart of the main stages in KRAS mutation testing for clinical use. Steps of the procedure performed by an
oncologist (yellow background), and steps performed by a pathologist (green background). (A, B) An example of the
raw amplification curves of KRAS wild-type (A) and mutant (B) samples tested using the TheraScreen PCR mutation kit.
(A, B) The curve on the farthest left (red) represents the amplification product of the wild-type (wt) control DNA
(exon 4). (B) The next curve to the right (green) represents the amplification product of the mutant template (p.G12A).
The small difference between the Cp values of the wild-type control DNA and the mutant DNA (∆Cp = 4.7 cycles) indicates
a mutation. (C) An example of the raw amplification curves (FAM fluorophore) of sample tested using the KRAS/BRAF
EntroGen mutation kit. The red curve (Cp = 24.96) represents amplification product of the BRAF V600E mutant DNA
(control DNA Cp = 23.68).
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ditional advantages of the TheraScreen PCR kit include
its fast turnaround time, user-friendly software-assisted
objective data interpretation, and one-step system that
prevents contamination [2].
The most important limitation of this kit is the rel-
atively high cost of the test per sample (~143 USD
[114]; ~210 USD in Poland; Table I) and high DNA
input requirements (Fig. 2).
PNAClamp. The PNAClamp mutation detection
kit (Panagene, Daejeon, Korea) is based on peptide nu-
cleic acid analog (PNA)-mediated real-time PCR
clamping technology. The higher specificity of PNA
binding to DNA, higher stability of a PNA-DNA du-
plex compared with the corresponding DNA-DNA
duplex, and inefficiency of PNA to act as a primer for
DNA polymerases are the bases for this technique [115].
PNA will hybridize to its complementary DNA tar-
get sequence only if the sequence is a complete
match. The PNA/DNA complex effectively blocks
the formation of a PCR product. On the other hand,
in the case of the mutant alleles, the melting temper-
ature of mismatched PNA-DNA hybrid is much
lower than the corresponding temperature of the nor-
mal PNA-DNA hybrid. Consequently, mutated se-
quences are preferentially amplified, and amplification
of the wild-type gene is suppressed [115, 116].
PNA-mediated PCR clamping significantly in-
creased the percentages of detected KRAS, BRAF, and
PIK3CAmutations compared with direct sequencing.
PNA-mediated PCR clamping increased the percent-
age of detected KRAS mutations by 7-11% [95, 96]
which implies that this method can detect minor sub-
populations of tumor cells with mutant alleles. The de-
tection of KRAS mutations in tumors of low cellular-
ity depends on the method used. Direct sequencing
revealed KRAS mutations in 11 out of 114 lung can-
cers (10%), whereas 10 additional mutations were de-
tected (18%) using PNA-mediated PCR clamping.
Of these mutations, five were detected in samples with
low tumor cellularity [97]. In addition, this method de-
tected more occult metastases in lymph nodes than stan-
dard HE analysis [117]. In another study [98],
the PNAClamp test detected mutations in 1%
of the mutant cells, while direct sequencing barely found
mutations in 20-50% of the mutant cells. The PNA-
Clamp test is a very sensitive method for detecting mu-
tants in a very small amount of DNA (optimal range:
10-25 ng of total DNA), and it is suitable for KRAS
mutation testing in small biopsy specimens (Fig. 2) [88,
98, 118].
The most important limitation of this kit is its in-
ability to determine type of mutation in codon 12.
StripAssay. A completely different type of test is
the StripAssay (Vienna Labs, Vienna, Austria). This test
combines mutant-enriched PCR based on PNA clamp-
ing and reverse-hybridization to nitrocellulose test strips
containing specific probes for the different mutations,
immobilized as an array of parallel lines. Bound bi-
otinylated sequences are detected using streptavidin-
alkaline phosphatase and color substrates with a LoD
of 1% mutants in a 99% wild-type background
[119]. Fifteen percent of the samples that were iden-
tified as KRAS-positive by this test were diagnosed as
wild-type by direct sequencing [120]. This test only
requires a water bath, fluorometer and thermocycler.
Today, it is difficult to imagine the laboratory of mol-
ecular pathology that would not be equipped with these
devices. The StripAssay test detects eight mutations
in codon 12 and two mutations in codon 13
of the KRAS oncogene (Table I). It is difficult to ex-
plain why two very rare mutations (p.G12I and
Fig. 2.An example of a discrepancy between the TheraScreen
PCR kit and the PNAClamp kit for KRAS mutation testing
resulting from insufficient DNA input for TheraScreen PCR
kit. The same DNA input (27.3 ng total DNA) from
the same patient was used for both kits. (A) The TheraScreen
amplification curve for wild-type control DNA (Cp = 33.82)
(red) indicates a low DNA input, thus very low-level
mutations may not be detected (a warning is displayed in
the test result). The next curve to the right (green) represents
the amplification product for mutant DNA (p.G13D);
nevertheless, if the Cp value is greater than or equal to 38 (as
in this case), it is classified as negative or beyond the LoD
of the kit and cannot be confidently interpreted as a mutation.
(B) The same amount of DNA input is optimal for
the PNAClamp kit (control Cp = 29.24; red) and a mutation
in codon 13 (green) is unequivocally detected.
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p.G12L) described in only five CRCs (according to
the COSMIC database v60) are detected by this test,
but other, much more frequent mutations are not.
The assay procedure is labor intensive (~6 h), be-
cause it requires several reaction steps: amplification,
hybridization, detection, and washing. Nevertheless,
the assay can be performed with standard laboratory
equipment; therefore, this approach appears to be an
interesting alternative to methods currently in use for
the detection of KRASmutations in DNA isolated from
FFPE tissue [120].
Cobas. This is a TaqMelt-based real-time PCR as-
say designed to detect the presence of 21 KRAS mu-
tations in codons 12, 13, and 61 (Table I) with a LoD
of approximately 5% mutants in a 95% wild-type back-
ground [110]. Mutation detection is achieved by melt-
ing curve analysis, using the Cobas 4800 System (Roche,
Branchburg, NJ, USA) with automated result inter-
pretation software. This test is highly reproducible be-
tween different clinical laboratories (98% concordant
results), requires 100 ng of total DNA input and is more
sensitive than both sequencing and the TheraScreen test
[121]. The additional 12 mutations detected by
the Cobas test, compared with the TheraScreen kit, rep-
resent approximately 2% of all KRASmutations. How-
ever, recent studies suggest that codon 61 mutations
may be more prevalent than reflected in the COSMIC
data [122, 123].
The most important limitation of this test is
the need for dedicated equipment.
Surveyor. This technology is based on a mis-
match-specific DNA endonuclease from celery (Surveyor
nuclease), which cleaves with high specificity at
the 3’side of any mismatch site in both DNA strands,
including all base substitutions and insertion/deletions
up to at least 12 nucleotides. Subsequently, DNA frag-
ments are analyzed with the WAVE HS System
[124]. The Surveyor kit (Transgenomic, Omaha,
USA) detects all mutations in exon 2 of the KRAS gene
(Table I) with a LoD of 1% mutants in a 99% wild-
type background [125]. Sequencing is required to con-
firm base changes.
The most important limitation of this test is
the need for dedicated equipment.
LightMix. This kit (TIB Molbiol, Berlin, Germany)
uses real-time PCR clamping technology and the melt-
ing curve method, with a LoD of 1% mutants in a 99%
wild-type background. Whitehall et al. [126] report-
ed that this kit detected a higher number of mutations
(59.5%) in FFPE tissue compared with fresh-frozen sam-
ples (38.8%). They also found incorrect KRAS muta-
tion types in 27% of the samples. Whitehall et al. [126]
concluded that although this kit performed reasonably
well with frozen tissue DNA, it yielded an unaccept-
ably high frequency of false-positive results with
FFPE samples.
Other (recently developed) assays
EntroGen. This kit (Tarzana, CA, USA) (Fig. 1.) is
based on the ARMS-PCR method and detects 11 mu-
tations (Table I) of the KRAS gene, with a LoD of
1% mutants in a 99% wild-type background. This test
increased the detection percentage of KRASmutations
by 3% compared with direct sequencing [99].
RealQuality RI-KRASMuST. This test (Ab Ana-
litica, Padua, Italy) detects the 7 most frequent mu-
tations (Table I) in the KRAS gene using real-time se-
quence-specific primer PCR assay. The LoD is 1%
mutants in a 99% wild-type background [100]. This
test increases the detection percentage of KRAS mu-
tation by 9% compared with direct sequencing [100].
Currently there are no published scientific reports
on the results of KRAS mutation testing in CRCs for
the following three assays (kits). (1) Hybcell Oncogenes
Tissue plexA (Anagnostics Bioanalysis, St. Valentin,
Austria) is based on compact sequencing and princi-
ples of microarrays (called hybcell arrays). Processing
is performed in a hyborg device. While traditional ar-
rays are printed on slides, the hybcell arrays are com-
posed of primers that are immobilized on the surface
of a cylinder. The test detects 7 common mutations
(Table I) with a LoD of 1-5% mutants in a 95-99%
wild-type background. The extended version of the test
includes an additional 25 KRAS mutations in codons
13, 61, and 146 and is under development. (2) Devyser
(Devyser, Hägersten, Sweden) uses multiplex allele-
specific PCR amplification for the identification of 12
KRASmutations (Table I). The LoD is 3% mutants in
a 97% wild-type background, according to the man-
ufacturer’s instructions. The PCR products are analyzed
using a capillary electrophoresis genetic analyzer.
(3) AmoyDx (Amoy Diagnostics, Xiamen, China)
is based on the ARMS-PCR method and detects
the 7 most common activating mutations (Table I)
of the KRAS gene in cancer tissue. The LoD is 1% mu-
tants in a 99% wild-type background, according to
the manufacturer’s instructions.
Comparison of KRAS diagnostic assays
Data comparing different diagnostic assays (CE-
IVD-marked) for KRAS mutation analysis are limit-
ed. A 95% concordance between the TheraScreen and
StripAssay tests [127] as well as a 98% concordance
between the TheraScreen and EntroGen tests [99] was
reported. Bando et al.’s [2] study, which mimicked
a real situation in a clinical genetic laboratory, demon-
strated high overall agreement between the Thera-
Screen and StripAssay tests. However, they noted an
excess of KRASmutations found by the StripAssay test
compared with the TheraScreen test, and they favored
the interpretation that the StripAssay test exhibits
a higher false-positive rate.
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In our view, the literature supports the statement
that currently the final choice of CE-IVD-marked
KRASmutation testing kit is largely dependent on
the laboratory equipment, experience and test cost.
To compare the test cost per sample we obtained price
quotes for kits available in Poland (August 2012).
The results are shown in Table I.
Unfortunately, the cost per sample may depend on
both the type of kit used and on the country where
the kit is sold. For example, the cost per sample for
the TheraScreen test is about USD 143 [114]. How-
ever, in Poland, the cost per sample of the same test
is about USD 210 (kit cost obtained from Syngen
Biotech, distributor of Qiagen in Poland). The high cost
makes it difficult to use this test in routine clinical prac-
tice.
The number of commercially available diagnostic
tests (CE-IVD-marked) will be increasing very rapid-
ly. Real-time PCR-based methods are simple and sen-
sitive, and will therefore be useful for molecular tests
of predictive clinical significance performed in the mol-
ecular laboratories of pathology departments. Further
studies by independent researchers are needed to com-
pare these tests, identify their advantages and disad-
vantages and suggest recommendations.
KRAS Quality Assurance Programs
In order to demonstrate competence and expertise
in molecular testing (as with all other laboratory tests),
quality assurance programs based on scientific evidence
are needed. There are two basic types of responsibil-
ity that are different but complementary, namely re-
sponsibility for the clinical (pathological) report and
responsibility for the technical aspects of the labora-
tory procedure. Both types of responsibility can be as-
sessed by external quality assurance (EQA) pro-
grams. EQA programs should be preceded by
the publication of the appropriate guidelines for
a particular test by scientific professional societies. Such
guidelines have already been published for KRASmu-
tation testing [46, 62].
External quality assessment is regarded as one
of the essential steps in the validation of clinical tests
[128]. Therefore, we believe that an evidence-based ap-
proach requires that laboratories performing KRAS tests
(and other molecular predictive tests of clinical sig-
nificance) be validated by EQA programs. Somatic mu-
tation tests containing predictive information and thus
of therapeutic consequences should be CE-IVD/FDA
approved, as has already been done with several com-
mercially available kits for testing KRASmutations (see
above). In this respect, the guidelines of the European
Society of Pathology would aid in the selection of spe-
cific technologies for routine KRAS testing in differ-
ent countries [59].
There is a need for EQA programs because:
1) Data comparing different KRASmutation assays are
limited.
2) Most but not all assays provide accurate results [129].
3) Currently, several commercially available assays are
in vitro diagnostic-certified for the detection of so-
matic KRASmutations in clinical practice and Con-
formité Européenne (CE)-marked. These assays
can be easily used in molecular laboratories of pathol-
ogy departments but their performance should be
rigorously monitored.
4) An EQA program provides an opportunity for lab-
oratories to evaluate their performance in KRAS test-
ing and to compare it with that of other laborato-
ries.
5) An EQA program may accelerate the harmonization
and unification of KRASmutation result reports to
ensure that the reports are informative for oncolo-
gists and patients.
6) Participation in an EQA program may help to iden-
tify errors in genotyping and develop methods to
eliminate them. The findings of the first phase
of the development of a European EQA scheme for
KRAS testing, in collaboration with the European
Society of Pathology showed that only ten out of 13
laboratories labeled all 14 test cases correctly;
the other laboratories made one to four mistakes. In
addition, the laboratories involved in that test
were selected based on their prominent position in
the field and all but one frequently performed KRAS
mutation testing for diagnostic purposes [47]. In an-
other study, an evaluation of the concordance be-
tween KRAS assays performed by 6 different labo-
ratories that tested 20 CRCs showed that consensus
scores of 100% and ≥ 83% (in all or 5/6 laborato-
ries) were reached in only 11/20 (55%) and 17/20
(85%) cases, respectively [130]. The main weakness
of this study compared with other reports [129, 131]
was that laboratories analyzed KRASmutations from
centrally isolated DNA but not from tumor sections
on glass slides. Thus, the results did not mimic clin-
ical testing procedures. In general, EQA programs
validate the expertise of a pathology laboratory in
performing particular molecular tests and also pro-
vide means for improvement. For example, although
10-15% of the laboratories made unacceptable mis-
takes during the first round of ESP KRAS EQA
scheme, after feedback, the labs performed signif-
icantly better [58].
7) A list of departments/laboratories that successful-
ly passed the ESP KRAS EQA scheme maintained
on the ESP website and on websites of the Nation-
al Societies of Pathology/Oncology (similar to
the Italian AIOM and SIAPEC websites [62]) will
help oncologists to choose the appropriate labora-
tory for KRASmutation testing. Additionally, this
information may help the appropriate institutions
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make decisions concerning reimbursement for
the cost of the test.
Thus, we believe that to achieve universal, high-qual-
ity standards for KRAS mutation testing and report-
ing, i.e., to ensure consistency and accuracy of results,
an evidence-based approach requires validation
of the performance of KRASmutation testing by var-
ious laboratories through EQA programs. In several
European countries (Germany, France, Italy, Spain,
Sweden, The Netherlands, and the United Kingdom),
national KRAS EQA programs have been organized un-
der the auspices and supervision of the National As-
sociations of Pathology and Oncology [47, 59]. Four
years ago, the European Society of Pathology, as an in-
ternational independent body, initiated a European
KRAS EQA scheme [46, 47, 63] in which laboratories
that performed the tests could participate irrespective
of the DNA extraction method and KRAS testing
method used. The ESP KRAS EQA scheme evaluat-
ed the correct identification of KRAS mutations, per-
centage of tumor cells and reporting of results.
The main purpose of this EQA scheme is to assess
the quality of KRAS testing. An additional but equal-
ly important aim is to provide a means for improve-
ment. The findings of the 2011 ESP KRAS EQA
scheme showed that 124 laboratories from 29 coun-
tries participated and 72% reported all 10 genotypes
correctly, including (for the first time) four laborato-
ries from Poland [132]: 1. Maria Skłodowska-Curie
Memorial Cancer Center and Institute of Oncology;
2. Jagiellonian University Medical College, Chair of Pa-
thology; 3. Oncogene Diagnostics; 4. Pomeranian Med-
ical University, Department of Pathology.
Revealing targets for personalized targeted
therapy is the pathologist’s domain
We would like to stress that we share the views
of Silke Lassmann and Martin Werner who recently stat-
ed that: “…the expertise in morphologically- and mo-
lecular-based analyses of human tissue specimens is
the pathologist’s treasure and will be of utmost clini-
cal relevance in terms of personalized medicine” [133].
The development of personalized targeted therapy is dif-
ficult because of the complex network of interactions
between multiple molecular pathways [134, 135]. Mo-
lecular alterations in these signaling pathways are just
beginning to be understood in the context of therapeutic
response. Pathologists are increasingly involved in
the analyses of molecular signaling pathways to reveal
targets of personalized targeted therapy, especially now
in an era where mutation-specific antibodies useful in
targeted therapy are ante portas (at the door) [136]. Per-
sonalized medicine means “The right drug, the right
dose, for the right patient, at the right time” [137], i.e.,
the matching of a particular therapy to specific molecular
features of a tumor. However, prior to the administration
of targeted drugs to suitable patients, predictive mo-
lecular or immunohistochemical diagnostic tests must
be conducted for both medical and economic reasons
(because most targeted drugs are very expensive). As
outlined above, the development of highly sensitive, sim-
ple, reliable, rapid, and compatible with FFPE tissue
KRASmutation assays, instead of adapting tissue sam-
pling and processing to research-derived molecular bi-
ology protocols, proved to be clinically useful.
KRAS testing may be regarded as a testing ground
indicating how pathologists of tomorrow should em-
brace effectively molecular technologies for the bene-
fit of cancer patients. As outlined above, pathologists
have the knowledge and expertise to identify par-
ticular gene mutations using the appropriate
available molecular tests. In addition, the ESP has
developed an EQA scheme to validate the exper-
tise of the laboratories that perform the molecu-
lar tests and confirm that they are competent in
this field. Indeed, this is an example of evidence-based
diagnostics in action.
While the clinical effectiveness of some targeted ther-
apies (including cetuximab for the first-line chemother-
apy of mCRC) has been proven, the cost/benefit ratio
of such treatments is still a matter of debate [138, 139].
There are currently no standards for the timing
of KRASmutation testing in CRC patients. Although
performing KRAS testing on all CRCs at the time
of surgery would be advisable (similarly to ER/PR HER2
testing in breast cancer), it may currently be difficult
to defend such an approach from a cost/effective point
of view. In France, the National Cancer Institute al-
located €2.5 million for KRASmutation screening only
in mCRC patients, to the 2008 budget [140]. It seems
reasonable to expect and suggest that the timing
of KRASmutation testing in CRC patients should de-
pend on the likelihood of metastatic disease in a pa-
tient with CRC at the time of operation. Postoperative
material from high-risk patients could be tested, due
to increased likelihood of the need to establish their
KRAS mutation status [31]. In any case, KRAS mu-
tation testing should be performed at the time of di-
agnosis of metastatic CRC [25, 31].
Conclusions
Pathologists should not be afraid of new molecular
technologies because only those simplified to “kits” are
currently certified for clinical purposes (and can easi-
ly be implemented). Sophisticated but very expensive
molecular technologies (next generation sequencing and
whole genome analysis) are currently only utilized in
research. When those technologies are simplified and
become much less expensive, they will also be ac-
commodated by those pathologists who are familiar
with the molecular tests now required in clinical on-
cology practice. Integrated histological diagnosis, en-
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riched by predictive information provided by molec-
ular assessments, is nothing new to pathologists;
what is new is the level of precision of predictive in-
formation provided by molecular analyses and the cost
of molecular tests and targeted treatments. KRAS test-
ing is just an example of a molecular test required for
the implementation of targeted therapy in a particu-
lar patient population. Pathologists must be ready to
perform the appropriate molecular and immunohis-
tochemical tests to facilitate the treatment decisions
made by oncologists for the benefit of patients.
In conclusion, based on the existing literature and
our own experience we would like to make the following
recommendations:
1. KRAS mutation testing (and other molecular tests
of clinical predictive significance) should be performed
by molecular laboratories in the pathology depart-
ments. This is because pathologists are responsible
for the final pathology reports of CRCs, which should
include predictive information. Sending paraffin
blocks away for testing is not in the best interest
of patients and is therefore not an optimal solution.
2. One of the commercially available CE-IVD-marked
or FDA-approved “kits” should be used for KRAS
mutation testing. The use of “in-house-developed
methods” is not an optimal solution and should be
avoided.
3. The sensitivity of direct sequencing for the analy-
sis of KRASmutations in FFPE tumor samples seems
to be too low to enable its use as a routine clinical
test. The use of direct sequencing is not an optimal
solution and should be avoided because, with this
method, up to approximately 25% of patients se-
lected for anti-EGFR therapy will not benefit.
4. Laboratories in the European Union performing
KRAS mutation testing for diagnostic (predictive)
purposes should periodically and continuously par-
ticipate in the ESP KRAS EQA scheme – a program
organized by an independent international body. Par-
ticipation should be obligatory. The previous ex-
periences of existing national EQA programs should
be exploited and utilized by organizers of the ESP
KRAS EQA scheme to reach a consensus on this is-
sue, which has very important consequences for pa-
tients, oncologists and pathologists.
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